MICHELLE TOMME: Open Payments
NPI 1467073379 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,072 in 72 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $941 · 2025 $1,072
Food & beverage: $1,072
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 8 | $160 |
| Otsuka America Pharmaceutical, Inc. | 11 | $145 |
| E.R. Squibb & Sons, L.L.C. | 8 | $144 |
| ABBVIE INC. | 19 | $136 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $107 |
| Janssen Pharmaceuticals, Inc | 5 | $96 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Collegium Pharmaceutical, Inc. | 3 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 1 | $29 |
Products named: FANAPT, COBENFY, VRAYLAR, CAPLYTA, INVEGA SUSTENNA, REXULTI, Auvelity, ABILIFY ASIMTUFII.
Industry payments across ID — which companies pay providers there.
